Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Summary

Primary Objective: \- To evaluate the safety and tolerability of ADXS-504 and to determine the MTD (maximum tolerated dose) or RP2D (recommended phase two dose) Secondary Objectives: * To characterize the immunological activity of ADXS-504, administered as; and to characterize the genomic profiles of study subjects * To evaluate the effects of ADXS-504 on change in PSA * To evaluate time to PSA progression

Timeline

Start

2021-08-12

Primary completion

2026-07

Completion

2028-07

Drugs

Indications